Harada, Hiroshi http://orcid.org/0000-0001-5121-6686
Fukuzawa, Nobuyuki
Abe, Toyofumi
Imamura, Ryoichi
Masaki, Noriyuki
Fujiyama, Nobuhiro
Sato, Shigeru
Hatakeyama, Shingo
Nishimura, Kenji
Kishikawa, Hidefumi
Iwami, Daiki
Hotta, Kiyohiko
Miura, Masayoshi
Ide, Kentaro
Nakamura, Michio
Kosoku, Akihiro
Uchida, Junji
Murakami, Taku
Tsuji, Takahiro
Funding for this research was provided by:
Multicenter Co-operational Clinical Study Fund of Japanese Society for Clinical Renal Transplantation (2017-2018)
Article History
Received: 23 September 2022
Accepted: 27 April 2023
First Online: 6 June 2023
Declarations
:
: T.M. has been employed by Hitachi Chemical Co. America, Ltd and has received wages. T.M. and H.H. filed patent applications related to this study. All authors except for T.M. and H.H. declare no conflict of interest in this study.
: The study has been performed in accordance with the Declaration of Helsinki and has been approved by the ethical committee of the principal institution, Sapporo City General Hospital (Development and nation-wide validation of kidney graft injury markers using urinary exosome and microvesicle: H28-053-319). Written informed consent was obtained from all patients, and we performed specimen management so that personal information was not identified in the case of specimen distribution.
: Not applicable.